What does this research mean for the field?

Peripheral blood mononuclear cell (PBMC) transcriptional profiling, particularly baseline CD4+ T cell levels and dynamic changes in macrophages and neutrophils, can noninvasively predict pathological complete response to neoadjuvant PARP inhibitor and immunotherapy in early HER2-negative breast cancer. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

This research aims to determine if immune profiling of PBMCs can predict the response to neoadjuvant therapy in early HER2-negative breast cancer.

May 30, 2026Journal of Clinical Oncology

Liquid biopsy with peripheral blood mononuclear cells: Deciphering systemic immunity to predict PARPi-immunotherapy efficacy in early HER2-negative breast cancer.

View Full Paper

Ask AI

Bookmark

This research aims to determine if immune profiling of PBMCs can predict the response to neoadjuvant therapy in early HER2-negative breast cancer.
Collected PBMC samples from 16 patients with HER2-negative breast cancer during neoadjuvant therapy.
Performed RNA sequencing and immune cell population estimation using various algorithms.
Analyzed changes in immune cell types and gene signatures in relation to treatment response.
Overall pCR rate was 56.25% (9/16 patients); pCR rates were 50% in luminal tumors and 75% in TNBC.
Higher levels of CD4⁺ T cells and memory T cells correlated with improved treatment response (p < 0.02).
Significant immune activation features were enriched in the pCR group compared to the non-pCR group.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Randomized trial investigates PBMC immune profiling to predict pCR in patients with HER2-negative breast cancer, suggesting a noninvasive biomarker approach.

Cite This Study

Kuang et al. (2026) studied this question.

synapsesocial.com/papers/6a1a808f0307b785094328ee https://doi.org/10.1200/jco.2026.44.16_suppl.e14531

View Full Paper

Ask AI

Bookmark

Implication

Randomized trial investigates PBMC immune profiling to predict pCR in patients with HER2-negative breast cancer, suggesting a noninvasive biomarker approach.

Liquid biopsy with peripheral blood mononuclear cells: Deciphering systemic immunity to predict PARPi-immunotherapy efficacy in early HER2-negative breast cancer.

Key Points

Discussion

Implication

Cite This Study

Liquid biopsy with peripheral blood mononuclear cells: Deciphering systemic immunity to predict PARPi-immunotherapy efficacy in early HER2-negative breast cancer.

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider